Top Markets
Coin of the day
Taysha Gene Therapies, Inc. Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc.

TSHA
株式のランク #6655
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and... Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
株価
$6.02
最終同期: 2026-08-27
時価総額
$1.93B
変化(1日)
0.00%
変化(1年)
112.72%
US
取引 Taysha Gene Therapies, Inc. (TSHA)

カテゴリー

Taysha Gene Therapies, Inc.(TSHA)の配当利回りの履歴
Taysha Gene Therapies, Inc.(銘柄コード: TSHA)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Taysha Gene Therapies, Inc.(TSHA)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)